The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma

Tyrosine kinase inhibitors (TKIs) are the backbone of the systemic treatment for patients with metastatic renal cell carcinoma (mRCC). TKIs such as pazopanib and cabozantinib can interact with other drugs concomitantly administered, particularly with proton-pump inhibitors (PPIs), possibly impacting...

Descripción completa

Detalles Bibliográficos
Autores principales: Buti, Sebastiano, Tommasi, Chiara, Scartabellati, Giulia, De Giorgi, Ugo, Brighi, Nicole, Rebuzzi, Sara Elena, Puglisi, Silvia, Caffo, Orazio, Kinspergher, Stefania, Mennitto, Alessia, Cattrini, Carlo, Santoni, Matteo, Verzoni, Elena, Rametta, Alessandro, Stellato, Marco, Malgeri, Andrea, Roviello, Giandomenico, de Filippo, Massimo, Cortellini, Alessio, Bersanelli, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760470/
https://www.ncbi.nlm.nih.gov/pubmed/36539370
http://dx.doi.org/10.1097/CAD.0000000000001356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760470/
https://www.ncbi.nlm.nih.gov/pubmed/36539370
http://dx.doi.org/10.1097/CAD.0000000000001356

Ejemplares similares